

2022

Wang, W., S. Kothari, M. Baay, S. M. Garland, A. R. Giuliano, M. Nygard, C. Velicer, J. Tota, A. Sinha, J. Skufca, T. Verstraeten and K. Sundstrom (2022). "Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources." *Expert Rev Vaccines* 21(2): 227-240.

10.1080/14760584.2022.2008243

Sharan, A., S. Jahagirdar, A. L. Stuurman, V. Elango, M. Riera-Montes, N. Kumar Kashyap, N. Kumar Arora, M. Mathai, P. Mangtani, H. Devlieger, S. Anderson, B. Whitaker, H. L. Wong, C. L. Cutland and C. Guillard Maure (2022). "Operational lessons learned in conducting an international study on pharmacovigilance in pregnancy in resource-constrained settings: the WHO Global Vaccine Safety Multi-Country Collaboration project." *Vaccine X*: 100160.

10.1016/j.jvacx.2022.100160

Kremsner, P. G., R. A. Ahuad Guerrero, E. Arana-Arri, G. J. Aroca Martinez, M. Bonten, R. Chandler, G. Corral, E. J. L. De Block, L. Ecker, J. J. Gabor, C. A. Garcia Lopez, L. Gonzales, M. A. Granados Gonzalez, N. Gorini, M. P. Grobusch, A. D. Hrabar, H. Junker, A. Kimura, C. F. Lanata, C. Lehmann, I. Leroux-Roels, P. Mann, M. F. Martinez-Resendez, T. J. Ochoa, C. A. Poy, M. J. Reyes Fentanes, L. M. Rivera Mejia, V. V. Ruiz Herrera, X. Saez-Llorens, O. Schonborn-Kellenberger, M. Schunk, A. Sierra Garcia, I. Vergara, T. Verstraeten, M. Vico, L. Oostvogels and H. S. Group (2022). "Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial." *Lancet Infect Dis* 22(3): 329-340.

10.1016/S1473-3099(21)00677-0

Izurietta, P., M. Scherbakov, J. Nieto Guevara, V. Vetter and L. Soumahoro (2022).

"Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media." *Hum Vaccin Immunother*: 1-18.

10.1080/21645515.2021.2013693

Chacon-Cruz, E., E. Meroc, S. A. Costa-Clemens, R. Clemens and T. Verstraeten (2022).

"Economic Evaluation of Universal Varicella Vaccination in Mexico." *Pediatr Infect Dis J* 41(5): 439-444. 10.1097/INF.0000000000003448

Carmona, A., M. Latorre Tejerina, A. Martínez Sebastián, D. Dobрева, C. P. Jurca, S. Huerta Barberá, V. Bernat Montoya, M. Aristoy Zabaleta, A. Pineda Caplliure, B. Mansilla Roig, M. Navío Anaya, R. Tosca-Segura, M. Tortajada-Girbés, J. Díez-Domingo and A. Orrico-Sánchez (2022). "Risk Measurement of Perinatal and Neonatal Morbidity Characteristics and Applicability of GAIA Case Definitions: Results and Lessons Learnt of a Hospital-Based Prospective Cohort Study in the Valencia Region (2019-2020)." *Int J Environ Res Public Health* 19(12): 7132. 10.3390/ijerph19127132

Bravo, L., I. Smolenov, H. H. Han, P. Li, R. Hosain, F. Rockhold, S. A. C. Clemens, C. Roa, Jr., C. Borja-Tabora, A. Quinsaat, P. Lopez, E. López-Medina, L. Brochado, E. A. Hernández, H. Reynales, T. Medina, H. Velasquez, L. B. Toloza, E. J. Rodriguez, D. I. M. de Salazar, C. A. Rodríguez, E. Sprinz, J. Cerbino-Neto, K. G. Luz, A. V. Schwarzbald, M. S. Paiva, J. Carlos, M. E. B. Montellano, M. R. A. de Los Reyes, C. Y. Yu, E. R. Alberto, M. M. Panaligan, M. Salvani-

Bautista, E. Buntinx, M. Hites, J. B. Martinot, Q. E. Bhorat, A. Badat, C. Baccharini, B. Hu, J. Jurgens, J. Engelbrecht, D. Ambrosino, P. Richmond, G. Siber, J. Liang and R. Clemens (2022). "Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial." *Lancet* 399(10323): 461-472. 10.1016/s0140-6736(22)00055-1

Bollaerts, K., M. A. Fletcher, J. A. Suaya, G. Hanquet, M. Baay and B. D. Gessner (2022). "Vaccine-Preventable Disease Incidence Based on Clinically, Radiologically, and Etiologically Confirmed Outcomes: Systematic Literature Review and Re-analysis of Pneumococcal Conjugate Vaccine Efficacy Trials." *Clin Infect Dis* 74(8): 1362-1371. 10.1093/cid/ciab649

Bettis, A. A., M. L'Azou Jackson, I. K. Yoon, J. G. Breugelmans, A. Goios, D. J. Gubler and A. M. Powers (2022). "The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines." *PLoS Negl Trop Dis* 16(1): e0010069. 10.1371/journal.pntd.0010069

2021

Willame, C., C. Dodd, L. van der Aa, G. Picelli, H. D. Emborg, J. Kahlert, R. Gini, C. Huerta, E. Martin-Merino, C. McGee, S. de Lusignan, G. Roberto, M. Villa, D. Weibel, L. Titievsky and M. Sturkenboom (2021). "Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project." *Drug Saf* 44(3): 383-395. 10.1007/s40264-020-01031-1

Waheed, D. E., J. Schiller, M. Stanley, E. L. Franco, M. Poljak, S. K. Kjaer, M. Del Pino, F. van der Klis, M. F. Schim van der Loeff, M. Baay, P. Van Damme and A. Vorsters (2021). "Human papillomavirus vaccination in adults: impact, opportunities and challenges - a meeting report." *BMC Proc* 15(Suppl 7): 16. 10.1186/s12919-021-00217-4

Vandeputte, J., P. Van Damme, J. Neyts, J. C. Audonnet, M. Baay and P. Neels (2021). "Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development?" *Biologicals* 73: 1-7. 10.1016/j.biologicals.2021.08.001

Vandeputte, J., M. Saville, M. Cavaleri, M. Friede, A. Hacker, S. O. Mueller, R. Rizzi, D. Smith, S. Thirstrup, R. Wagner, M. Baay and P. Neels (2021). "IABS/CEPI platform technology webinar: Is it possible to reduce the vaccine development time?" *Biologicals* 71: 55-60. 10.1016/j.biologicals.2021.04.005

Suaya, J. A., M. A. Fletcher, L. Georgalis, A. G. Arguedas, J. M. McLaughlin, G. Ferreira, C. Theilacker, B. D. Gessner and T. Verstraeten (2021). "Identification of *Streptococcus pneumoniae* in hospital-acquired pneumonia in adults." *J Hosp Infect* 108: 146-157. 10.1016/j.jhin.2020.09.036

Stuurman, A. L., A. Sharan, S. Jahagirdar, V. Elango, M. Riera-Montes, N. Kashyap, J. Bicler, R. Poluru, N. Arora, M. Mathai, P. Mangtani, H. DeVlieger, S. Anderson, B. Whitaker, H. L. Wong, C. Cutland, C. Guillard Maure and W. G. M. Sites (2021). "WHO global vaccine safety multi-country collaboration project on safety in pregnancy: Assessing the level of diagnostic

certainty using standardized case definitions for perinatal and neonatal outcomes and maternal immunization." *Vaccine* 9: 100123. 10.1016/j.jvax.2021.100123

Stuurman, A. L., C. Rizzo and M. Haag (2021). "Investigating the procurement system for understanding seasonal influenza vaccine brand availability in Europe." *PLoS One* 16(4): e0248943. 10.1371/journal.pone.0248943

Stuurman, A. L., S. Ciampini, A. Vannacci, A. Bella, C. Rizzo, C. Munoz-Quiles, E. Pandolfi, H. Liyanage, M. Haag, M. Redlberger-Fritz, R. Bonaiuti and P. Beutels (2021). "Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK." *PLoS One* 16(6): e0252836. 10.1371/journal.pone.0252836

Stuurman, A. L., J. Bicler, A. Carmona, A. Descamps, J. Diez-Domingo, C. Munoz Quiles, H. Nohynek, C. Rizzo, M. Riera-Montes and D. P. Partners (2021). "Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe - Results from the DRIVE EU study platform." *Vaccine* 39(29): 3964-3973. 10.1016/j.vaccine.2021.05.059

Safadi, M. A., M. Riera-Montes, L. Bravo, A. Tangsathapornpong, R. Lagos, U. Thisyakorn, A. C. Linhares, R. Capeding, O. Prommalikit, T. Verstraeten and M. O'Ryan (2021). "The burden of norovirus disease in children: a multi-country study in Chile, Brazil, Thailand and the Philippines." *Int J Infect Dis* 109: 77-84. 10.1016/j.ijid.2021.06.037

Saegerman, C., A. F. Donneau, N. Speybroeck, A. N. Diep, A. Williams, L. Stamatakis, W. Coppieters, F. Michel, C. Breuer, M. Dandoy, O. Ek, C. Gourzones, J. Schyns, E. Goffin, F. Minner, V. Renault, L. Gillet and F. Bureau (2021). "Repetitive saliva-based mass screening as a tool for controlling SARS-CoV-2 transmission in nursing homes." *Transbound Emerg Dis*. 10.1111/tbed.14280

Saegerman, C., A. F. Donneau, N. Speybroeck, A. N. Diep, A. Williams, L. Stamatakis, W. Coppieters, F. Michel, C. Breuer, M. Dandoy, O. Ek, C. Gourzones, J. Schyns, E. Goffin, F. Minner, V. Renault, L. Gillet and F. Bureau (2021). "Repetitive saliva-based mass screening as a tool for controlling SARS-CoV-2 transmission in nursing homes." *Transbound Emerg Dis*. 10.1111/tbed.14280

Poljak, M., K. Cuschieri, D. E. Waheed, M. Baay and A. Vorsters (2021). "Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening." *Acta Dermatovenerol Alp Pannonica Adriat* 30(1): 21-26.

Pawaskar, M., E. Meroc, S. Samant, E. Flem, G. Bencina, M. Riera-Montes and U. Heininger (2021). "Economic burden of varicella in Europe in the absence of universal varicella vaccination." *BMC Public Health* 21(1): 2312. 10.1186/s12889-021-12343-x

Meroc, E., J. Froberg, T. Almasi, B. A. Winje, A. Orrico-Sanchez, A. Steens, S. A. McDonald, K. Bollaerts and M. J. Knol (2021). "European data sources for computing burden of (potential) vaccine-preventable diseases in ageing adults." *BMC Infect Dis* 21(1): 345. 10.1186/s12879-021-06017-7

Kremsner, P. G., P. Mann, A. Kroidl, I. Leroux-Roels, C. Schindler, J. J. Gabor, M. Schunk, G. Leroux-Roels, J. J. Bosch, R. Fendel, A. Kreidenweiss, T. P. Velavan, M. Fotin-Mleczeck, S. O.

Mueller, G. Quintini, O. Schonborn-Kellenberger, D. Vahrenhorst, T. Verstraeten, M. Alves de Mesquita, L. Walz, O. O. Wolz, L. Oostvogels and C.-N.-S. Group (2021). "Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial." *Wien Klin Wochenschr* 133(17-18): 931-941. 10.1007/s00508-021-01922-y

Eigner, U., T. Verstraeten and J. Weil (2021). "Decrease in norovirus infections in Germany following COVID-19 containment measures." *J Infect* 82(6): 276-316. 10.1016/j.jinf.2021.02.012

Carmona, A., C. Munoz-Quiles, A. Stuurman, A. Descamps, A. Mira-Iglesias, L. Torcel-Pagnon and J. Diez-Domingo (2021). "Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project." *Int J Environ Res Public Health* 18(3). 10.3390/ijerph18031058

Calduch, E. N., T. Cattaert and T. Verstraeten (2021). "Model estimates of hospitalization discharge rates for norovirus gastroenteritis in Europe, 2004-2015." *BMC Infect Dis* 21(1): 757. 10.1186/s12879-021-06421-z

Bonten, M., T. Verstraeten, S. Gravenstein and J. Poolman (2021). "Reply to Baird and Douglas." *Clin Infect Dis* 72(9): e436. 10.1093/cid/ciaa1106

Bonten, M., J. R. Johnson, A. H. J. van den Biggelaar, L. Georgalis, J. Geurtsen, P. I. de Palacios, S. Gravenstein, T. Verstraeten, P. Hermans and J. T. Poolman (2021). "Epidemiology of Escherichia coli Bacteremia: A Systematic Literature Review." *Clin Infect Dis* 72(7): 1211-1219. 10.1093/cid/ciaa210

Biccler, J., K. Bollaerts, P. Vora, E. Sole, L. A. G. Rodriguez, A. Lanas, R. E. Langley and M. S. Gabarro (2021). "Public health impact of low-dose aspirin on colorectal cancer, cardiovascular disease and safety in the UK - Results from micro-simulation model." *Int J Cardiol Heart Vasc* 36: 100851. 10.1016/j.ijcha.2021.100851

Bekeredjian-Ding, I., J. H. Trouvin, H. Depraetere, C. La, A. E. Suvarnapunya, A. Bell, A. Mann, P. Meij, J. M. Bethony, L. Schellhaas, W. B. Nazziwa, E. Karikari-Boateng, J. S. Prachumsri, P. Salmikangas, D. Smith, P. Stjarnkvist, W. Van Molle, M. Baay and P. Neels (2021). "Controlled Human Infection Studies: Proposals for guidance on how to design, develop and produce a challenge strain." *Biologicals* 74: 16-23. 10.1016/j.biologicals.2021.09.002

Beer, M., L. Amery, B. J. Bosch, A. Brix, O. Daramola, S. Inman, C. Jungbäck, J. Kortekaas, V. Lindo, U. Okorji-Obike, S. Rodriguez-Conde, A. Tang, R. Tchelet, J. Vandeputte, P. J. Wichgers Schreur, A. Osterhaus, B. Haagmans and J. C. Audonnet (2021). "Zoonoses Anticipation and Preparedness Initiative, stakeholders conference, February 4 & 5, 2021." *Biologicals* 74: 10-15. 10.1016/j.biologicals.2021.10.003

Baay, M. and P. Neels (2021). "Controlled Human Infection to Speed Up SARS-CoV-2 Vaccine Development." *Front Immunol* 12: 658783. 10.3389/fimmu.2021.658783

Baay, M., B. Lina, A. Fontanet, A. Marchant, M. Saville, P. Sabot, J. Vandeputte and P. Neels (2021). "Virology, epidemiology, immunology and vaccine development of SARS-CoV-2,

update after nine months of pandemic." *Biologicals* 69: 76-82.
10.1016/j.biologicals.2020.11.003

Alexandridou, M., T. Cattaert and T. Verstraeten (2021). "Estimation of Risk of Death Attributable to Acute Gastroenteritis Not Caused by *Clostridioides difficile* Infection Among Hospitalized Adults in England." *Clin Epidemiol* 13: 309-315. 10.2147/CLEP.S296516

2020

Vorsters, A., F. X. Bosch, P. Bonanni, E. L. Franco, M. Baay, C. Simas, D. E. Waheed, C. Castro, R. Murillo, L. Trujillo, C. Wiesner and N. Munoz (2020). "Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report." *BMC Proc* 14(Suppl 9): 8. 10.1186/s12919-020-00192-2

Verstraeten, T., M. A. Fletcher, J. A. Suaya, S. Jackson, C. K. Hall-Murray, D. A. Scott, B. Schmole-Thoma, R. E. Isturiz and B. D. Gessner (2020). "Diabetes mellitus as a vaccine-effect modifier: a review." *Expert Rev Vaccines* 19(5): 445-453. 10.1080/14760584.2020.1760098

Van Baarle, D., K. Bollaerts, G. Del Giudice, S. Lockhart, C. Luxemburger, M. J. Postma, A. Timen, B. Standaert and I. D. i. t. A. P. c. Vaccines (2020). "Preventing infectious diseases for healthy ageing: The VITAL public-private partnership project." *Vaccine* 38(37): 5896-5904. 10.1016/j.vaccine.2020.07.005

Tin Tin Htar, M., S. Jackson, P. Balmer, L. C. Serra, A. Vyse, M. Slack, M. Riera-Montes, D. L. Swerdlow and J. Findlow (2020). "Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs." *BMC Public Health* 20(1): 1890. 10.1186/s12889-020-09946-1

Stuurman, A. L., K. Bollaerts, M. Alexandridou, J. Bicler, J. Diez Domingo, H. Nohynek, C. Rizzo, T. Turunen, M. Riera-Montes and D. P. Partners (2020). "Vaccine effectiveness against laboratory-confirmed influenza in Europe - Results from the DRIVE network during season 2018/19." *Vaccine* 38(41): 6455-6463. 10.1016/j.vaccine.2020.07.063

Sturkenboom, M., T. Braeye, L. van der Aa, G. Danieli, C. Dodd, T. Duarte-Salles, H. D. Emborg, M. Gheorghe, J. Kahlert, R. Gini, C. Huerta, E. Martín-Merino, C. McGee, S. de Lusignan, G. Picelli, G. Roberto, L. Tramontan, M. Villa, D. Weibel and L. Titievsky (2020). "ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations." *Vaccine*. 10.1016/j.vaccine.2020.01.100

Pollard, A. J., R. Sauerwein, M. Baay, P. Neels, H. C. T. speakers and c. session (2020). "Third human challenge trial conference, Oxford, United Kingdom, February 6-7, 2020, a meeting report." *Biologicals* 66: 41-52. 10.1016/j.biologicals.2020.04.004

Khan, A. S., J. Blumel, D. Deforce, M. F. Gruber, C. Jungback, I. Knezevic, L. Mallet, D. Mackay, J. Matthijssens, M. O'Leary, S. Theuns, J. Victoria and P. Neels (2020). "Report of the second international conference on next generation sequencing for adventitious virus detection in biologics for humans and animals." *Biologicals* 67: 94-111. 10.1016/j.biologicals.2020.06.002

Hall, G. C., S. Lanes, K. Bollaerts, X. Zhou, G. Ferreira and R. Gini (2020). "Outcome misclassification: Impact, usual practice in pharmacoepidemiology database studies and an online aid to correct biased estimates of risk ratio or cumulative incidence." *Pharmacoepidemiology and Drug Safety* 29(11): 1450-1455. 10.1002/pds.5109

Ferreira, G., A. L. Stuurman, Y. Horsmans, T. Cattaert, T. Verstraeten, Y. Feng, D. Rosillon and A. Guignard (2020). "Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink." *Eur J Gastroenterol Hepatol* 32(1): 101-109. 10.1097/MEG.0000000000001537

Dodd, C., M. de Ridder, D. Weibel, O. Mahaux, F. Haguinet, T. de Smedt, S. de Lusignan, C. McGee, T. Duarte-Salles, H. D. Emborg, C. Huerta, E. Martín-Merino, G. Picelli, K. Berencsi, G. Danieli and M. Sturkenboom (2020). "ADVANCE system testing: Estimating the incidence of adverse events following pertussis vaccination in healthcare databases with incomplete exposure data." *Vaccine*. 10.1016/j.vaccine.2020.03.050

Braeye, T., H. D. Emborg, A. Llorente-Garcia, C. Huerta, E. Martin-Merino, T. Duarte-Salles, G. Danieli, L. Tramontan, D. Weibel, C. McGee, M. Villa, R. Gini, M. Lehtinen, L. Titievsky and M. Sturkenboom (2020). "Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries - The ADVANCE project." *Vaccine* 38(16): 3243-3254. 10.1016/j.vaccine.2020.02.082

Bourke, A., W. G. Dixon, A. Roddam, K. J. Lin, G. C. Hall, J. R. Curtis, S. N. van der Veer, M. Soriano-Gabarro, J. K. Mills, J. M. Major, T. Verstraeten, M. J. Francis and D. B. Bartels (2020). "Incorporating patient generated health data into pharmacoepidemiological research." *Pharmacoepidemiol Drug Saf* 29(12): 1540-1549. 10.1002/pds.5169

Bollaerts, K., A. Rekkas, T. De Smedt, C. Dodd, N. Andrews and R. Gini (2020). "Disease misclassification in electronic healthcare database studies: Deriving validity indices-A contribution from the ADVANCE project." *PLoS One* 15(4): e0231333. 10.1371/journal.pone.0231333

Bekeredjian-Ding, I., W. Van Molle, M. Baay, P. Neels, P. E. I. speakers and c. session (2020). "Human challenge trial workshop: Focus on quality requirements for challenge agents, Langen, Germany, October 22, 2019." *Biologicals* 66: 53-61. 10.1016/j.biologicals.2020.04.005

Baay, M. and P. Neels (2020). "SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues." *Biologicals* 67: 69-74. 10.1016/j.biologicals.2020.08.006

Baay, M., B. Lina, A. Fontanet, A. Marchant, M. Saville, P. Sabot, P. Duclos, J. Vandeputte and P. Neels (2020). "SARS-CoV-2: Virology, epidemiology, immunology and vaccine development." *Biologicals* 66: 35-40. 10.1016/j.biologicals.2020.06.005

Arora, N. K., M. K. Das, R. Poluru, N. K. Kashyap, T. Mathew, J. Mathai, M. K. Aggarwal, P. Haldar, T. Verstraeten, P. L. F. Zuber and I. V. S. S. Group (2020). "A Prospective Cohort

Study on the Safety of Infant Pentavalent (DTwP-HBV-Hib) and Oral Polio Vaccines in Two South Indian Districts." *Pediatr Infect Dis J* 39(5): 389-396. 10.1097/INF.0000000000002594

Arlegui, H., K. Bollaerts, F. Salvo, V. Bauchau, G. Nachbaur, B. Begaud and N. Praet (2020). "Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines." *Drug Saf* 43(11): 1089-1104. 10.1007/s40264-020-00984-7

Arlegui, H., K. Bollaerts, V. Bauchau, G. Nachbaur, B. Begaud and N. Praet (2020). "Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)." *Drug Saf* 43(11): 1105-1120. 10.1007/s40264-020-00982-9

2019

Weibel, D., C. Dodd, O. Mahaux, F. Haguinet, T. De Smedt, T. Duarte-Salles, G. Picelli, L. Tramontan, G. Danieli, A. Correa, C. McGee, E. Martin-Merino, C. Huerta, K. Berencsi, H. D. Emborg, K. Bollaerts, V. Bauchau, L. Titievsky and M. Sturkenboom (2019). "ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination." *Vaccine*. 10.1016/j.vaccine.2019.06.040

Vorsters, A., P. Bonanni, H. C. Maltezou, J. Yarwood, N. T. Brewer, F. X. Bosch, S. Hanley, R. Cameron, E. L. Franco, M. Arbyn, N. Munoz, M. Kojouharova, J. Pattyn, M. Baay, E. Karafillakis and P. Van Damme (2019). "The role of healthcare providers in HPV vaccination programs - A meeting report." *Papillomavirus Res* 8: 100183. 10.1016/j.pvr.2019.100183

Tin Tin Htar, M., A. H. J. van Den Biggelaar, H. Sings, G. Ferreira, M. Moffatt, C. Hall-Murray, T. Verstraeten, B. D. Gessner, H. J. Schmitt and L. Jodar (2019). "The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review." *Expert Rev Vaccines* 18(10): 1069-1089. 10.1080/14760584.2019.1676155

Tin Tin Htar, M., M. de Ridder, T. Braeye, A. Correa, C. McGee, S. de Lusignan, T. Duarte-Salles, C. Huerta, E. Martin-Merino, L. Tramontan, G. Danieli, G. Picelli, N. van der Maas, K. Berencsi, L. Arnheim-Dahlstrom, U. Heininger, H. D. Emborg, D. Weibel, K. Bollaerts and M. Sturkenboom (2019). "Advance system testing: Vaccine benefit studies using multi-country electronic health data - The example of pertussis vaccination." *Vaccine*. 10.1016/j.vaccine.2019.08.078

Sturkenboom, M., P. Bahri, A. Chiacchiuni, T. Grove Krause, S. Hahne, A. Khromava, M. Kokki, P. Kramarz, X. Kurz, H. J. Larson, S. de Lusignan, P. Mahy, L. Torcel-Pagnon, L. Titievsky and V. Bauchau (2019). "Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines." *Vaccine*. 10.1016/j.vaccine.2019.07.081

Spoulou, V., S. Alain, G. Gabutti, C. Giaquinto, J. Liese, F. Martinon-Torres and T. Vesikari (2019). "Implementing Universal Varicella Vaccination in Europe: The Path Forward." *Pediatr Infect Dis J* 38(2): 181-188. 10.1097/inf.0000000000002233

Marley, C., Y. El Hahi, G. Ferreira, L. Woods and A. Ramirez Villaescusa (2019). "Evaluation of a risk score to predict future Clostridium difficile disease using UK primary care and hospital data in Clinical Practice Research Datalink." Hum Vaccin Immunother: 1-7. 10.1080/21645515.2019.1589288

Gini, R., C. N. Dodd, K. Bollaerts, C. Bartolini, G. Roberto, C. Huerta-Alvarez, E. Martin-Merino, T. Duarte-Salles, G. Picelli, L. Tramontan, G. Danieli, A. Correa, C. McGee, B. F. H. Becker, C. Switzer, S. Gandhi-Banga, J. Bauwens, N. A. T. van der Maas, G. Spiteri, E. Sdoná, D. Weibel and M. Sturkenboom (2019). "Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project." Vaccine. 10.1016/j.vaccine.2019.07.045

Emborg, H. D., J. Kahlert, T. Braeye, J. Bauwens, K. Bollaerts, G. Danieli, T. Duarte-Salles, S. Glismann, C. Huerta, S. de Lusignan, E. Martin, C. McGee, A. Correa, L. Tramontan, D. Weibel and M. Sturkenboom (2019). "ADVANCE system testing: Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases: An example." Vaccine. 10.1016/j.vaccine.2019.07.039

Curran, D., M. Hunjan, A. El Ghachi, Y. El-Hahi, V. Bianco and G. Ferreira (2019). "Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis." BMJ Open 9(8): e023502. 10.1136/bmjopen-2018-023502

Cargnel, M., Y. Van der Stede, A. Haegeman, I. De Leeuw, K. De Clercq, E. Méroc and S. Welby (2019). "Effectiveness and cost-benefit study to encourage herd owners in a cost sharing vaccination programme against bluetongue serotype-8 in Belgium." Transbound Emerg Dis 66(1): 400-411. 10.1111/tbed.13034

Braeye, T., V. Bauchau, M. Sturkenboom, H. D. Emborg, A. L. Garcia, C. Huerta, E. M. Merino and K. Bollaerts (2019). "Estimation of vaccination coverage from electronic healthcare records; methods performance evaluation - A contribution of the ADVANCE-project." PLoS One 14(9): e0222296. 10.1371/journal.pone.0222296

Bollaerts, K., T. Verstraeten and C. Cohet (2019). "Observational studies of non-specific effects of Diphtheria-Tetanus-Pertussis vaccines in low-income countries: Assessing the potential impact of study characteristics, bias and confounding through meta-regression." Vaccine 37(1): 34-40. 10.1016/j.vaccine.2018.11.049

Bollaerts, K., E. Ledent, T. de Smedt, D. Weibel, H. D. Emborg, G. Danieli, T. Duarte-Salles, C. Huerta, E. Martin-Merino, G. Picelli, L. Tramontan, M. Sturkenboom and V. Bauchau (2019). "ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling." Vaccine. 10.1016/j.vaccine.2019.09.034

Bollaerts, K., T. de Smedt, C. McGee, H. D. Emborg, M. Villa, M. Alexandridou, T. Duarte-Salles, R. Gini, C. Bartolini, S. de Lusignan, M. Tin Tin Htar, L. Titievsky, M. Sturkenboom and V. Bauchau (2019). "ADVANCE: Towards near real-time monitoring of vaccination coverage, benefits and risks using European electronic health record databases." Vaccine. 10.1016/j.vaccine.2019.08.012

Bollaerts, K., M. Alexandridou and T. Verstraeten (2019). "Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England." *Vaccine: X* 1(11 April 2019): 100007.

2018

Yanni, E. A., G. Ferreira, M. Guennec, Y. El Hahi, A. El Ghachi, F. Haguinet, E. Espie and V. Bianco (2018). "Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012." *BMJ Open* 8(6): e020528. 10.1136/bmjopen-2017-020528

Verstraeten, T., M. Baay and K. Bollaerts (2018). Opportunities and challenges in characterizing the safety of new adjuvants. MVAf. Leiden.

van den Biggelaar, A., H. Sings, G. Ferreira, M. Tin Tin Htar, M. Moffatt, E. Negro-Calduch, B. Gessner, H.-J. Schmitt and L. Jodar (2018). Evidence of early impact of routine paediatric immunization with 13-valent pneumococcal conjugate vaccine on antimicrobial resistant pneumococcal diseases. *ESPID*. Malmö.

Stuurman, A. L., M. Riera, S. Lamprianou, S. Perez-Vilar, S. A. Anderson, P. Mangtani, H. Devlieger, T. Verstraeten, P. L. F. Zuber and C. Guillard Maure (2018). "Vaccine safety surveillance in pregnancy in low- and middle-income countries using GAIA case definitions: A feasibility assessment." *Vaccine* 36(45): 6736-6743. 10.1016/j.vaccine.2018.09.033

Stuurman, A. L., M. Riera, S. Lamprianou, S. Perez-Vilar, S. A. Anderson, P. Mangtani, H. Devlieger, T. Verstraeten, P. Zuber and C. G. Maure (2018). Vaccine Safety Surveillance In Pregnancy Using Gaia Definitions For Neonatal Conditions: A Feasibility Assessment In Low- And Middle-Income Countries. *ISOP*. Geneva.

Stuurman, A., C. Rizzo and M. Haag (2018). Seasonal influenza vaccine procurement systems in Europe. *EPH*. Ljubljana.

Sturkenboom, M. (2018). "Advancing collaborative vaccine benefits and safety research in Europe via the ADVANCE code of conduct." *Vaccine* 36(2): 194-195. 10.1016/j.vaccine.2017.08.043

Skufca, J., M. Baay, G. Yen, S. Kothari, R. Drury and V. C (2018). A systematic literature review update of the impact and effectiveness of the quadrivalent human papillomavirus vaccine on cervical abnormalities. *Eurogin*. Lisbon.

Skufca, J., M. Baay, G. Yen, S. Kothari, R. Drury and V. C (2018). Effectiveness and Impact of the Quadrivalent Human Papillomavirus Vaccine on Anogenital Warts: A Systematic Literature Review Update. International papillomavirus conference. Sydney.

Skufca, J., M. Baay, G. Yen, S. Kothari, R. Drury and V. C (2018). Impact and effectiveness of the quadrivalent human papillomavirus vaccine on cervical abnormalities: a systematic literature review update. International papillomavirus conference. Sydney.

Safadi, M. A., M. Riera-Montes, L. Bravo, A. Tangsathapornpong, R. Lagos, A. Linares, R. Capeding, O. Prommalikit, M. O’Ryan and T. Verstraeten (2018). The burden of norovirus disease in children: a multi-country study in Chile, Brazil, Thailand and the Philippines. ESPID. Malmo.

Riera-Montes, M., M. O’Ryan and T. Verstraeten (2018). "Norovirus and Rotavirus disease severity in children: Systematic Review and Meta-Analysis." *Pediatr Infect Dis J* 37(6): 501-505. 10.1097/inf.0000000000001824

Pircon, J. Y., C. A. Talarico, K. Bollaerts, W. P. Hausdorff and C. J. Clarke (2018). "The choice of analytical methodology can alter conclusions regarding herd effects of paediatric pneumococcal vaccination programmes." *Vaccine* 36(46): 6933-6943. 10.1016/j.vaccine.2018.10.003

Petry, K. U., K. Bollaerts, P. Bonanni, M. Stanley, R. Drury, E. Joura, S. K. Kjaer, C. Meijer, D. Riethmuller, B. Soubeyrand, P. Van Damme and X. Bosch (2018). "Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine." *Hum Vaccin Immunother* 14(7): 1800-1806. 10.1080/21645515.2018.1450125

Negro-Calduch, E., T. Cattaert, M. Riera-Montes and V. T (2018). Rotavirus-Associated Hospital Discharge Rates from 2004 to 2015 in Europe. ASM-Microbe. Atlanta.

Negro-Calduch, E., T. Cattaert, M. Riera-Montes and V. T (2018). Hospitalisations for acute gastroenteritis equally due to norovirus, rotavirus and *Clostridium difficile* in Europe. ECCMID. Madrid.

McDonald, S. A., D. Nijsten, K. Bollaerts, J. Bauwens, N. Praet, M. van der Sande, V. Bauchau, T. de Smedt, M. Sturkenboom and S. Hahne (2018). "Methodology for computing the burden of disease of adverse events following immunization." *Pharmacoepidemiol Drug Saf* 27(7): 724-730. 10.1002/pds.4419

Lindsay, L., H. L. DuPont, C. L. Moe, M. Alberer, C. Hatz, A. E. Kirby, H. M. Wu, T. Verstraeten and R. Steffen (2018). "Estimating the incidence of norovirus acute gastroenteritis among US and European international travelers to areas of moderate to high risk of traveler's diarrhea: a prospective cohort study protocol." *BMC Infect Dis* 18(1): 605. 10.1186/s12879-018-3461-6

Kowalzik, F., H. Binder, D. Zoller, M. Riera-Montes, R. Clemens, T. Verstraeten and F. Zepp (2018). "Norovirus Gastroenteritis among Hospitalized Patients, Germany, 2007-2012." *Emerg Infect Dis* 24(11): 2021-2028. 10.3201/eid2411.170820

Hermans et al. (2018). Patients at Risk of Invasive Extraintestinal Pathogenic *Escherichia coli* Disease: A Systematic Literature Review. SHEA. Portland.

Hermans, ..., van den Biggelaar, ..., Verstraeten and ... (2018). The O serogroup epidemiology of invasive extraintestinal *E coli* infections: a systematic literature review. ASM- Microbe. Atlanta.

Gravenstein, S., A. L. Stuurman, L. Georgalis, M. Bonten, J. R. Johnson, P. I. d. Palacios, J. Poolman, P. Hermans and T. Verstraeten (2018). The Burden of Disease Associated with Invasive Extra-Intestinal E. coli Infections in Adults: A Systematic Literature Review. EUGMS. Berlin.

Gini, R., S. Lanes, V. Mehta, X. Zhou, G. Ferreira, M. Reynolds and H. G. C (2018). How is outcome misclassification addressed in pharmacoepidemiology database studies? ICPE. Prague, Czech Republic.

Ferreira, G. L. C., C. Marano, L. De Moerlooze, A. Guignard, Y. Feng, Y. El Hahi and T. van Staa (2018). "Incidence and prevalence of hepatitis B in patients with diabetes mellitus in the UK: A population-based cohort study using the UK Clinical Practice Research Datalink." *J Viral Hepat* 25(5): 571-581. 10.1111/jvh.12841

De Smedt, T., E. Merrall, D. Macina, S. Perez-Vilar, N. Andrews and K. Bollaerts (2018). "Bias due to differential and non-differential disease- and exposure misclassification in studies of vaccine effectiveness." *PLoS One* 13(6): e0199180. 10.1371/journal.pone.0199180

Chang, C. H., M. Sakaguchi, J. Weil and T. Verstraeten (2018). "The incidence of medically-attended norovirus gastro-enteritis in Japan: Modelling using a medical care insurance claims database." *PLoS One* 13(3): e0195164. 10.1371/journal.pone.0195164

Bruffaerts, N., T. De Smedt, A. Delcloo, K. Simons, L. Hoebeke, C. Verstraeten, A. Van Nieuwenhuysse, A. Packeu and M. Hendrickx (2018). "Comparative long-term trend analysis of daily weather conditions with daily pollen concentrations in Brussels, Belgium." *Int J Biometeorol* 62(3): 483-491. 10.1007/s00484-017-1457-3

Bollaerts K et al. (2018). ADVANCE system testing: benefit-risk analysis of a marketed vaccine using cohort modelling and MCDA swing weighting. ICPE. Prague.

Bollaerts, K., T. Verstraeten and C. Cohet (2018). Observational studies on non-specific effects (NSE) of Diphtheria-Tetanus-Pertussis vaccination (DTP) in low-income countries: assessing the impact of bias and confounding by using meta-regression. ICPE. Prague.

Bollaerts, K., T. De Smedt, K. Donegan, L. Titievsky and V. Bauchau (2018). "Benefit-Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project." *Drug Saf* 41(8): 775-786. 10.1007/s40264-018-0658-y

Baay, M. F. D., T. L. Richie and P. Neels (2018). "Human challenge trials in vaccine development, Rockville, MD, USA, September 28-30, 2017." *Biologicals pii: S1045-1056(18)30039-3*. . 10.1016/j.biologicals.2018.02.002

Baay, M., J. Skufca, G. Yen, S. Kothari, R. Drury, G. Perez Amaya and V. C (2018). Impact and effectiveness of the quadrivalent human papillomavirus vaccine on oral and anal HPV infections and recurrent respiratory papillomatosis. Eurogin. Lisbon.

Baay, M., K. Bollaerts and T. Verstraeten (2018). Safety Of Newly Adjuvanted Vaccines Among Older Adults, A Systematic Literature Review And Meta-Analysis. ICPE. Prague.

Baay, M., K. Bollaerts and T. Verstraeten (2018). "A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults." *Vaccine* 36(29): 4207-4214. 10.1016/j.vaccine.2018.06.004

Alexandridou, M. V., Thomas; Bollaerts, Kaatje (2018). Risk factors of zoster vaccine failure among elderly in England. ICPE. Prague.

Alexandridou, M., T. Verstraeten, M. Riera-Montes and K. Bollaerts (2018). Risk factors of zoster vaccine failure among elderly in England. ECCMID. Madrid.

2017

Vorsters, A., M. Arbyn, M. Baay, X. Bosch, S. de Sanjose, S. Hanley, E. Karafillakis, P. L. Lopalco, K. G. Pollock, J. Yarwood and P. Van Damme (2017). "Overcoming barriers in HPV vaccination and screening programs." *Papillomavirus Res* 4: 45-53. 10.1016/j.pvr.2017.07.001

Verstraeten, T., E. Negro Calduch, T. Cattaert and J. Weil (2017). Norovirus-associated hospital discharge rates in Europe, 2004-2015. VED. Faro, Portugal.

Verstraeten, T., T. Cattaert and M. Riera (2017). Risk Of Death Attributable To Acute Gastro-Enteritis Among Hospitalized Elderly Patients In England. IAGG. San Francisco.

Verstraeten, T., T. Cattaert and M. Riera (2017). Rotavirus Vaccination Of Infants May Reduce Acute Gastroenteritis Rates In The Elderly In England. IAGG. San Francisco.

Verstraeten, T., T. Cattaert, J. Harris, B. Lopman, C. C. Tam and G. Ferreira (2017). "Estimating the Burden of Medically Attended Norovirus Gastroenteritis: Modeling Linked Primary Care and Hospitalization Datasets." *J Infect Dis* 216(8): 957-965. 10.1093/infdis/jix410

Verstraeten, T., T. Cattaert, J. Harris, B. Lopman, C. Tam and G. Ferreira (2017). Using The CPRD And HES Linked Datasets To Derive The Burden Of Medically Attended Norovirus-Attributable Acute Gastroenteritis In England. ICPE. Montreal, Canada. .

Verstraeten, T., T. Cattaert and G. Ferreira (2017). Gender inequality in acute gastroenteritis rates in England. ISPOR. Glasgow, UK. .

Verstraeten, T., M. Alexandridou, T. Cattaert and G. Ferreira (2017). All-cause Mortality Among Hospitalized Patients In England Attributable To Acute Gastro-Enteritis Not Caused By Clostridium Difficile. VED. Faro, Portugal.

Torcel-Pagnon, L., H. Bricout, I. Bertrand, E. Perinetti, E. Franco, G. Gabutti and A. Volpi (2017). "Impact of Underlying Conditions on Zoster-Related Pain and on Quality of Life Following Zoster." *J Gerontol A Biol Sci Med Sci* 72(8): 1091-1097. 10.1093/gerona/glw189

Tin Tin Htar, M., A. L. Stuurman, G. Ferreira, C. Alicino, K. Bollaerts, C. Paganino, R. R. Reinert, H. J. Schmitt, C. Trucchi, T. Verstraeten and F. Ansaldi (2017). "Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-

analyses of observational studies." PLoS One 12(5): e0177985.
10.1371/journal.pone.0177985

Stuurman, A. L., T. Verstraeten and A. De Schryver (2017). Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study. IVW 2017. Lausanne.

Stuurman, A. L., T. Verstraeten and A. De Schryver (2017). "Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study." Expert Rev Vaccines 16(2): 187-191. 10.1080/14760584.2017.1264272

Riera-Montes, M., T. Cattaert and T. Verstraeten (2017). Rotavirus vaccination may reduce acute gastroenteritis rates across all age groups in England. ISPOR. Glasgow, UK. .

Riera-Montes, M., T. Cattaert and T. Verstraeten (2017). Rotavirus Vaccination May Reduce Acute Gastroenteritis Rates Across All Age Groups In England ICPE. Montreal, Canada. .

Riera-Montes, M., T. Cattaert and T. Verstraeten (2017). Continued decrease of all cause gastroenteritis episodes in primary care in vaccinated and unvaccinated children in the UK three years after rotavirus vaccine introduction. ESPID. Madrid.

Riera-Montes, M., T. Cattaert, G. Ferreira and T. Verstraeten (2017). Rotavirus vaccination may reduce acute gastroenteritis rates across all age groups in the UK. VED. Faro, Portugal.

Riera-Montes, M., K. Bollaerts, U. Heininger, N. Hens, G. Gabutti, A. Gil, B. Nozad, G. Mirinaviciute, E. Flem, A. Souverain, T. Verstraeten and S. Hartwig (2017). "Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization." BMC Infect Dis 17(1): 353. 10.1186/s12879-017-2445-2

Riera-Montes, M. (2017). Impact of rotavirus vaccination in the UK: a real effect or an ecological artefact? ESCAIDE. Stockholm, Sweden.

O'Ryan, M., M. Riera-Montes and B. Lopman (2017). "Norovirus in Latin America: Systematic Review and Meta-analysis." Pediatr Infect Dis J 36(2): 127-134.
10.1097/INF.0000000000001369

Maguire, A., M. E. Johnson, D. W. Denning, G. L. C. Ferreira and A. Cassidy (2017). "Identifying rare diseases using electronic medical records: the example of allergic bronchopulmonary aspergillosis." Pharmacoepidemiol Drug Saf 26(7): 785-791.
10.1002/pds.4204

Lescrauwaet, B., E. Miserocchi, S. Thurau, B. Bodaghi, L. Duchateau, T. Verstraeten and S. Srivastava (2017). "Association Between Visual Function Response and Reduction of Inflammation in Noninfectious Uveitis of the Posterior Segment." Invest Ophthalmol Vis Sci 58(9): 3555-3562. 10.1167/iovs.17-22049

Lescrauwaet, B., L. Duchateau, T. Verstraeten and T. L. Jackson (2017). "Visual Function Response to Ocriciplasmin for the Treatment of Vitreomacular Traction and Macular Hole: The OASIS Study." Invest Ophthalmol Vis Sci 58(13): 5842-5848. 10.1167/iovs.17-22363

Jackson, T. L., T. Verstraeten, L. Duchateau and B. Lescauwat (2017). "Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole." *Acta Ophthalmol* 95(8): e740-e745. 10.1111/aos.13369

Fj, K., D. Zöller, H. Binder, R. Clemens, T. Verstraeten and F. Zepp (2017). Norovirus Gastroenteritis Is An Important Cause Of Nosocomial Infections In Germany. IAGG. San Francisco.

Demoury, C., T. De Smedt, H. De Schutter, M. Sonck, N. Van Damme, K. Bollaerts, G. Molenberghs, L. Van Bladel and A. Van Nieuwenhuysse (2017). "Thyroid Cancer Incidence around the Belgian Nuclear Sites, 2000-2014." *Int J Environ Res Public Health* 14(9). 10.3390/ijerph14090988

Chang, C., M. Sakaguchi, T. Verstraeten and J. Weil (2017). The burden of medically attended acute gastro-enteritis due to norovirus in Japan – results from a database analysis. VED. Faro, Portugal.

Cattaert, T., G. Ferreira and T. Verstraeten (2017). Increased Episode Rate Of Medically-Attended Acute Gastroenteritis In Diabetics in England. ISPOR. Glasgow, UK. .

Cattaert, T., G. Ferreira and T. Verstraeten (2017). Increased Episode Rate Of Medically-Attended Acute Gastroenteritis In Diabetics in England. ICPE. Montreal, Canada. .

Bollaerts, K. e. a. (2017). A systematic review of methodological approaches ICPE. Montreal, Canada.

Bollaerts, K. e. a. (2017). Methodology to estimate the health burden of adverse events following immunization: a contribution from ADVANCE. ICPE. Montreal, Canada.

Bollaerts, K. e. a. (2017). Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization. ESPID. Madrid.

Bollaerts, K., M. Riera-Montes, U. Heininger, N. Hens, A. Souverain, T. Verstraeten and S. Hartwig (2017). "A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data." *Epidemiol Infect* 145(13): 2666-2677. 10.1017/S0950268817001546

Bollaerts, K., T. De Smedt, K. Donegan, V. Baucha and T. L (2017). Near real-time monitoring of the anticipated benefit-risk of vaccines using an interactive dashboard: a proposition from ADVANCE. ISOP. Liverpool, UK.

Bollaerts, K. (2017). Algorithms to identify pertussis in 4 European primary care databases - the ADVANCE project. ICPE. Montreal, Canada.

Bollaerts, K. (2017). Analytical interrelations between validity indices for validation of case-finding algorithms in healthcare data research: a contribution from ADVANCE. ICPE. Montreal, Canada.

Baay, M., K. Bollaerts, C. Struchiner and T. Verstraeten (2017). "Background rates of disease in Latin American children from a rotavirus vaccine study." *Hum Vaccin Immunother* 13(8): 1916-1920. 10.1080/21645515.2017.1320007

Alexandridou, M., T. Cattaert, G. Ferreira and V. T (2017). Estimation Of Risk Of Death Attributable To Acute Gastro-Enteritis Among Hospitalized Adults In England. ICPE. Montreal.

Alexandridou, M. and K. Bollaerts (2017). Zoster vaccine effectiveness against incident herpes zoster and postherpetic neuralgia in elderly in the UK. ISV. Paris, France.

Alexandridou, M. and K. Bollaerts (2017). Zoster vaccine effectiveness against incident herpes zoster and postherpetic neuralgia in elderly in the UK. ISPOR. Glasgow, UK. .

2016

Willame, C., L. Baril, J. van den Bosch, G. L. Ferreira, R. Williams, D. Rosillon and C. Cohet (2016). "Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies." *Pharmacoepidemiol Drug Saf* 25(12): 1397-1406. 10.1002/pds.4081

Verstraeten, T., B. Jiang, J. G. Weil and J. H. Lin (2016). "Modelling Estimates of Norovirus Disease in Patients with Chronic Medical Conditions." *PLoS One* 11(7): e0158822. 10.1371/journal.pone.0158822

Verstraeten, T., C. Cohet, G. Dos Santos, G. L. Ferreira, K. Bollaerts, V. Bauchau and V. Shinde (2016). "Pandemrix and narcolepsy: A critical appraisal of the observational studies." *Hum Vaccin Immunother* 12(1): 187-193. 10.1080/21645515.2015.1068486

Verstraeten, T., T. Cattaert, J. Harris, B. Lopman, C. Tam and G. Ferreira (2016). Medically Attended Norovirus Disease In England: Estimates From 2007-2013 Using The CPRD. Calicivirus. Savanna, Georgia, USA.

Van Damme, P., P. Bonanni, F. X. Bosch, E. Joura, S. K. Kjaer, C. J. Meijer, K. U. Petry, B. Soubeyrand, T. Verstraeten and M. Stanley (2016). Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Eurogin. Salzburg, Austria.

Van Damme, P., P. Bonanni, F. X. Bosch, E. Joura, S. K. Kjaer, C. J. Meijer, K. U. Petry, B. Soubeyrand, T. Verstraeten and M. Stanley (2016). "Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines." *Vaccine* 34(6): 757-761. 10.1016/j.vaccine.2015.12.063

Stassijns, J., K. Bollaerts, M. Baay and T. Verstraeten (2016). "A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children." *Vaccine* 34(6): 714-722. 10.1016/j.vaccine.2015.12.024

Riera, M., T. Cattaert, G. Ferreira and T. Verstraeten (2016). Use of surveillance databases to describe influenza epidemiology in Europe. ISPOR. Vienna, Austria. .

Petry, K. U., K. Bollaerts, P. Bonanni, F. X. Bosch, R. Drury, E. Joura, S. K. Kjaer, C. J. Meijer, D. Riethmuller, B. Soubeyrand, P. Van Damme and M. Stanley (2016). Evaluation of the individual residual risk of cervical cancer after vaccination with Gardasil9. Eurogin. Salzburg, Austria.

O’Ryan, M., M. Riera-Montes and B. Lopman (2016). The burden of norovirus in Latin America. Calicivirus. Savanna, Georgia, USA.

O’Ryan, M., V. Blazevic, L. Hernandez-Donoso and M. Riera-Montes (2016). Norovirus seroprevalence and antibody avidity in Chilean infants. Calicivirus. Savanna, Georgia, USA.

Negro Calduch, E., M. Riera-Montes and T. Verstraeten (2016). Genotype distribution of noroviruses associated with sporadic gastroenteritis in Europe. ESCAIDE. Stockholm.

Merrall, E., D. Macina, S. Perez-Vilar, K. Bollaerts and t. A. initiative (2016). Disease and exposure misclassification in studies of vaccine effectiveness: a simulation tool. ICPE. Dublin, Ireland.

Marcelon, L., T. Verstraeten, G. Dominiak-Felden and F. Simondon (2016). "Quantitative benefit-risk assessment by MCDA of the quadrivalent HPV vaccine for preventing anal cancer in males." *Expert Rev Vaccines* 15(1): 139-148. 10.1586/14760584.2016.1107480

Kowalzik, F. and et al. (2016). Norovirus Disease Leads to Higher Hospitalization Rates in Older Adults with Chronic Medical Condition. FIS/HIS. Edinburgh, Scotland.

Garland, S. M., S. K. Kjaer, N. Munoz, S. L. Block, D. R. Brown, M. J. DiNubile, B. R. Lindsay, B. J. Kuter, G. Perez, G. Dominiak-Felden, A. J. Saah, R. Drury, R. Das and C. Velicer (2016). "Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience." *Clin Infect Dis* 63(4): 519-527. 10.1093/cid/ciw354

Ferreira, G., T. Cattaert and T. Verstraeten (2016). Burden of medically attended acute gastroenteritis in England: a cohort study in CPRD. ISPOR. Vienna, Austria. .

Dos Santos, G., F. Haguinet, C. Cohet, D. Webb, J. Logie, G. L. Ferreira, D. Rosillon and V. Shinde (2016). "Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: A self-controlled case-series." *Vaccine* 34(31): 3598-3606. 10.1016/j.vaccine.2016.05.016

Cattaert, T., Ferreira, Germano LC;, K. Bollaerts and T. Verstraeten (2016). Seasonality of Guillain-Barré Syndrome in the United Kingdom from April 2005 to March 2015. ICPE. Dublin.

Brauchli Pernus, Y., C. Nan, T. Verstraeten, M. Pedenko, O. U. Osokogu, D. Weibel, M. Sturkenboom, J. Bonhoeffer and G. consortium (2016). "Reference set for performance testing of pediatric vaccine safety signal detection methods and systems." *Vaccine* 34(51): 6626-6633. 10.1016/j.vaccine.2015.10.013

Bollaerts, K. and the ADVANCE initiative (2016). New methods to estimate vaccination coverage from health care databases. ICPE. Dublin, Ireland.

Bollaerts, K., V. Shinde, G. Dos Santos, G. Ferreira, V. Bauchau, C. Cohet and T. Verstraeten (2016). "Application of Probabilistic Multiple-Bias Analyses to a Cohort- and a Case-Control Study on the Association between Pandemrix and Narcolepsy." PLoS One 11(2): e0149289. 10.1371/journal.pone.0149289

Baay, M., K. Bollaerts, C. Struchiner and T. Verstraeten (2016). Using the Clinical Study Data Request initiative to investigate rates of serious adverse events in Latin American infants. VACC10. Amsterdam, The Netherlands.

2015

Riera-Montes, M., M. O'Ryan, T. Vesikari and T. Verstraeten (2015). Norovirus disease severity is comparable to rotavirus disease in children in medical setting. World Society for Pediatric Infectious Diseases. Rio de Janeiro, Brazil.

Lindsay, L., J. Wolter, I. De Coster, P. Van Damme and T. Verstraeten (2015). The risk of norovirus disease in adults aged 65 and above. AGS. National Harbor, USA.

Lindsay, L., J. Wolter, I. De Coster, P. Van Damme and T. Verstraeten (2015). "A decade of norovirus disease risk among older adults in upper-middle and high income countries: a systematic review." BMC Infect Dis 15: 425. 10.1186/s12879-015-1168-5

Lescrauwaet, B., L. Duchateau, T. Verstraeten and S. Thureau (2015). Improved Visual Function Is Associated With Inflammation Reduction In Subjects With Non-Infectious Uveitis (Niu) of The Posterior Segment Treated With Intravitreal Sirolimus: Results From Sakura Study 1. ISPOR Europe. Milan, Italy.

Kowalzik, F., M. Riera-Montes, T. Verstraeten and F. Zepp (2015). "The burden of norovirus disease in children in the European Union." *Pediatr Infect Dis J* 34(3): 229-234. 10.1097/INF.0000000000000546

Kowalzik, F., K. Frank, M. Riera-Montes, D. Zöller, R. Clemens, Z. F and V. T (2015). Norovirus-associated hospitalizations among older adults, Germany 2007-2012. European Union Geriatric Medicine Society. Oslo, Norway.

Bollaerts, K., V. Shinde, G. Dos Santos, G. Ferreira, V. Bauchau, C. Cohet and T. Verstraeten (2015). Probabilistic Multiple-Bias Analyses of Observational Studies on Narcolepsy Following Vaccination With GlaxoSmithKline's Inactivated Adjuvanted (AS03) A/H1N1pdm09 Pandemic Influenza Vaccine. ICPE. Boston, USA.

2014

Verstraeten, T., F. Simondon, G. Dominiak-Felden and L. Marcelon (2014). Quantitative Benefit-Risk Assessment of the Quadrivalent HPV Vaccine for the Prevention of Anal Cancer in Males – Method ICPE. Taipei, Taiwan.

Marcelon, L., T. Verstraeten, F. Simondon and G. Dominiak-Felden (2014). Quantitative Benefit-Risk Assessment of the Quadrivalent HPV Vaccine for the Prevention of Anal Cancer in Males – Results IPV. Seattle, USA.

Marcelon, L., T. Verstraeten, F. Simondon and G. Dominiak-Felden (2014). Quantitative Benefit-Risk Assessment of the Quadrivalent HPV Vaccine for the Prevention of Anal Cancer in Males – Results ICPE. Taipei, Taiwan.

2013

Van Holle, L., Z. Zeinoun, V. Bauchau and T. Verstraeten (2012). "Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study." *Pharmacoepidemiol Drug Saf* 21(6): 603-610. 10.1002/pds.3226

Heikkinen, T., J. Young, E. van Beek, H. Franke, T. Verstraeten, J. G. Weil and G. Della Cioppa (2012). "Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study." *Am J Obstet Gynecol* 207(3): 177 e171-178. 10.1016/j.ajog.2012.07.007